Rachel Kohls
Clinical Nurse Specialist · Austin, TXNPI 1275907024
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,041 of the $3,631 with a category attached, or 83.8%. 34 manufacturers reported payments, led by Medtronic at 38.1% of the total. 2025 is the largest year on record at $1,649, 6.3 times the $263 reported in 2021. Among clinical nurse specialist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$329
- Abbott$235
- Lilly USA, LLC$228
- Dexcom, Inc.$144
- Amgen$120
- plus $1K from 28 others
What the payments were for
- Travel & lodging$57816%
- Food & beverage$3,04184%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 42 | $1,385 |
| Novo Nordisk | 20 | $329 |
| Abbott | 10 | $235 |
| Lilly USA, LLC | 12 | $228 |
| Dexcom, Inc. | 7 | $144 |
| Amgen(2 entities) | 6 | $120 |
| Bayer | 6 | $107 |
| AbbVie | 5 | $86 |
| BETA Bionics, Inc. | 2 | $82 |
| Corcept Therapeutics | 4 | $81 |
| Insulet Corporation | 4 | $76 |
| Novartis | 3 | $66 |
| Ascensia Diabetes Care US Inc. | 3 | $64 |
| Cequr Corporation | 2 | $59 |
| AstraZeneca | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| IBSA Pharma Inc. | 3 | $52 |
| Antares Pharma, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Soleno Therapeutics, Inc. | 1 | $32 |
| Acella Pharmaceuticals, LLC | 2 | $30 |
| Mannkind Corporation | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $22 |
| Vistapharm, Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Intuity Medical Inc | 1 | $17 |
| Alvogen Inc | 1 | $17 |
| Halozyme Inc | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,631 in reported general payments places this provider in the 90th percentile of 88 clinical nurse specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 452 | $649,904 |
| OzempicSemaglutide | 251 | $380,777 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 140 | $166,068 |
| TrulicityDulaglutide | 99 | $136,696 |
| JardianceEmpagliflozin | 129 | $135,128 |
| FarxigaDapagliflozin Propanediol | 92 | $111,249 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $104,659 |
| Tresiba Flextouch U-200Insulin Degludec | 91 | $85,417 |
| Xigduo XrDapaglifloz Propaned/Metformin | 43 | $60,660 |
| ForteoTeriparatide | 11 | $43,036 |
| RybelsusSemaglutide | 19 | $40,926 |
| Repatha SureclickEvolocumab | 34 | $37,423 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $34,963 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $30,384 |
| KerendiaFinerenone | 21 | $28,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $228 | $842,512615 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $329 | $433,775284 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $37 | $301,196269 claims |
| AstraZenecaFarxiga | $58 | $111,24992 claims |
| BayerKerendia | $107 | $28,59321 claims |
| AbbVieSynthroid | $86 | $7,59985 claims |
| Cequr CorporationCequr Simplicity | $59 | $7,57914 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $3,491239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 88 clinical nurse specialist providers in Texas.
Other clinical nurse specialist in Austin
- Rebecca MontiAustin$53K
- Martha QuintonAustin$6K
- Benjamin PaganoAustin$4K
- Donna PrebleAustin$4K
- Chloe Marien-CaseyAustin$2K
- Emily BeddingfieldAustin$2K
- Adrienne BrennerAustin$2K
- Haiyan LiuAustin$2K
- Judith ChedvilleAustin$2K
- Susanne MorrisAustin$763
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.